Rising Prevalence Of Chronic Diseases Fuels Growth In The Duchenne Muscular Dystrophy Market: A Key Catalyst Accelerating Duchenne Muscular Dystrophy Market Growth in 2025

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Duchenne Muscular Dystrophy Industry Market Size Be by 2025?
The market for Duchenne muscular dystrophy has seen a robust growth in the past few years. The market is projected to expand from $1.16 billion in 2024 to $1.26 billion in 2025, with a compound annual growth rate (CAGR) of 8.9%. The growth during the historical period is credited to advancements in genetic comprehension and diagnosis, progression in clinical trials, increased patient advocacy and awareness, incentives and recognition for orphan drugs, and joint research initiatives.

What's the Long-Term Growth Forecast for the Duchenne Muscular Dystrophy Market Size Through 2029?
Expectations are high for a substantial expansion in the duchenne muscular dystrophy market in the coming years, with projections indicating it will reach $1.75 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 8.5%. The predicted surge during the forecast period is predominantly due to ongoing developments in gene therapies, precision medicine strategies, greater access to treatments, continuous long-term research and regulatory improvements. The forecast period is likely to witness certain trends such as the adoption of digital health technologies, advancements in therapeutic technologies, gene therapies and genetic medicines, regulatory endorsement for orphan drugs and precision medicine methodologies.

View the full report here:
https://www.thebusinessresearchcompany.com/report/duchenne-muscular-dystrophy-global-market-report

What Are the Key Growth Drivers Fueling the Duchenne Muscular Dystrophy Market Expansion?
The upward trend in chronic diseases is anticipated to boost the expansion of the Duchenne muscular dystrophy market in the coming years. Chronic diseases are health ailments or conditions with prolonged symptoms that endure for a minimum of one year. Duchenne muscular dystrophy fulfills the particular therapeutic demands of people suffering from this genetic affliction, underscoring the larger importance of personalized medicine in managing and potentially reducing the consequences of chronic conditions. To illustrate, in January 2023, the National Library of Medicine, a United States government agency, predicted that the quantity of US individuals aged 50 and above with at least one chronic condition will escalate to 142.66 million by 2050. Consequently, the growing incidence of chronic diseases is fuelling the Duchenne muscular dystrophy market's growth.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=10368&type=smp

What Are the Key Trends Driving Duchenne Muscular Dystrophy Market Growth?
Duchenne muscular dystrophy market's leading businesses are innovating with techniques like clinical trial design, enhancing drug development efficiency & effectiveness, improving patient outcomes and speeding up approval for novel therapies. The process of clinical trial design involves outlining a clinical study to assess new treatment efficacy and safety. It includes setting objectives, choosing participants, and developing methods & analyses. For example, in March 2024, the Critical Path Institute (C-Path), a non-profit based in the US, introduced the DMD Clinical Trial Simulator (CTS). The Duchenne Regulatory Science Consortium of C-Path developed this advanced tool to refine DMD therapy efficacy studies' layout. The CTS has notable elements, such as advanced modeling of functional test performance, the ability to simulate various circumstances, enhanced efficiency in trial design, and public accessibility through the C-Path website and Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP). Consequently, it stands as a crucial resource for pharmaceutical companies and researchers immersed in DMD study.

How Is the Duchenne Muscular Dystrophy Market Segmented?
The duchenne muscular dystrophy market covered in this report is segmented -

1) By Therapy: Mutation Suppression, Exon Skipping Approach
2) By Therapeutic Class: Molecular Based Therapies, Steroid Therapy
3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
5) By End User: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:
1) By Mutation Suppression: Antisense Oligonucleotides (ASOs), Small Molecules, Gene Therapy
2) By Exon Skipping Approach: Exon-Skipping Therapies, Combination Therapies, Clinical Trials And Investigational Drugs

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=10368&type=smp

Which Companies Are Leading the Charge in Duchenne Muscular Dystrophy Market Innovation?
Major companies operating in the duchenne muscular dystrophy market include Pfizer Inc., GlaxoSmithKline plc, PerkinElmer Inc., BioMarin Pharmaceutical Inc., Sarepta Therapeutics Inc., PTC Therapeutics Inc., Asklepios BioPharmaceutical Inc., Catabasis Pharmaceuticals Inc., Wave Life Sciences Ltd., Bristol Myers Squibb Company, BridgeBio Pharma Inc., Rocket Pharmaceuticals Inc., Italfarmaco SpA, Solid Biosciences Inc., Avidity Biosciences Inc., Fulcrum Therapeutics Inc., Akashi Therapeutics Inc., WAVE Life Sciences Ltd., Capricor Therapeutics Inc., Santhera Pharmaceuticals Holding, Armagen Technologies Inc., Dyne Therapeutics Inc., Benitec Biopharma Limited, Edgewise Therapeutics Inc.

Which Regions Are Leading the Global Duchenne Muscular Dystrophy Market in Revenue?
North America was the largest region in the Duchenne muscular dystrophy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the global duchenne muscular dystrophy market during the forecast period. The regions covered in the duchenne muscular dystrophy market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=10368

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 7882 955267,
Asia: +91 88972 63534,
Americas: +1 310-496-7795 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.